Outcome of rare primary malignant bone sarcoma (RPMBS) treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study (EURO-BOSS)

Article Pathology

Primary Osseous Leiomyosarcoma with Vertebral and Nodal Metastasis in a Young Woman: A Rare Case Report

Saikat Mitra et al.

Summary: Primary leiomyosarcoma of bone is rare, especially in young patients. It can mimic common tumors like osteosarcoma in terms of clinical and radiological features. This case study describes a patient who initially presented with knee pain and swelling, and was later found to have vertebral and nodal metastasis.

INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2023)

添加到收藏夹

Article Pathology

Malignant Mesenchymoma Revisited A Clinicopathologic Study of Leiomyosarcomas With Osteosarcomatous Differentiation

Sanhong Yu et al.

Summary: This study evaluated the clinicopathologic features of leiomyosarcoma (LMS) with heterologous osteosarcomatous differentiation (OS). The results showed that LMS with OS is exceptionally rare and highly aggressive with poor outcomes, occurring in both primary tumors and metastases.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2022)

添加到收藏夹

Article Oncology

Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities

Silvia Stacchiotti et al.

Summary: Ultra-rare sarcomas, defined as those with an incidence of <= 1 per 1,000,000, present unique challenges in diagnosis, disease biology understanding, clinical evidence generation, and therapy authorization, affecting a significant number of patients.

CANCER (2021)

添加到收藏夹

Article Oncology

Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study

Ivar Hompland et al.

Summary: Adding intensive chemotherapy to surgery for the treatment of patients with dedifferentiated chondrosarcoma (DDCS) is feasible and results in favorable survival outcomes compared to previous reports. Despite the limitations of non-controlled trial data, it can be concluded that chemotherapy may be considered in the management of patients over 40 years old.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Oncology